Company / Current Liabilities
Candel Therapeutics, Inc. Current Liabilities History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$14.2M
FY2023
5-year range
$5.4M / $14.2M
FY2021-FY2023
Trend
+152.6%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $5M to $14M over the past 2 years.
Based on SEC 10-K filings.
$14M in FY2023.
Increased from $5M to $14M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, current liabilities increased 152.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $14.2M | +152.6% |
| FY2022 | $5.6M | +4.7% |
| FY2021 | $5.4M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026